(1R,2S)-2-amino-1-phenylpentan-1-ol | 1034247-52-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (1R,2S)-2-amino-1-phenylpentan-1-ol
• 英文别名: (1R,2S)-2-amino-1-phenylbutan-1-ol
• CAS: 1034247-52-3
• 化学式: C₁₁H₁₇NO
• 分子量: 179.262
• InChiKey: JBCQBAFOLVIDBV-WDEREUQCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1R,2S)-2-amino-1-phenylpentan-1-ol 、 5-(5-iodo-1H-indazol-1-yl)-1-methylpyridin-2(1H)-one 在 copper(l) iodide 、 caesium carbonate 作用下， 反应 3.0h， 以66%的产率得到5-(5-((1R,2S)-2-amino-1-phenylpentyloxy)-1H-indazol-1-yl)-1-methylpyridin-2(1H)-one
  参考文献：
  名称：

  Discovery of a Novel Oral Glucocorticoid Receptor Modulator (AZD9567) with Improved Side Effect Profile

  摘要：

  Synthetic glucocorticoids (GC) are essential for the treatment of a broad range of inflammatory diseases. However, their use is limited by target related adverse effects on, e.g., glucose homeostasis and bone metabolism. Starting from a nonsteroidal GR ligand (4) that is a full agonist in reporter gene assays, we exploited key functional triggers within the receptor, generating a range of structurally diverse partial agonists. Of these, only a narrow subset exhibited full anti-inflammatory efficacy and a significantly reduced impact on adverse effect markers in human cell assays compared to prednisolone. This led to the discovery of AZD9567 (15) with excellent in vivo efficacy when dosed orally in a rat model of joint inflammation. Compound 15 is currently being evaluated in clinical trials comparing the efficacy and side effect markers with those of prednisolone.

  DOI：

  10.1021/acs.jmedchem.7b01690

文献信息

• Chemical compounds 572
  申请人：Berger Markus

  公开号：US20080214641A1

  公开（公告）日：2008-09-04

  Compounds of formula (I): The present invention relates to novel indazolyl ester or amide derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments

  化合物公式（I）：本发明涉及新型吲唑酯或酰胺衍生物，涉及包含这些衍生物的制药组合物，涉及制备这些新型衍生物的过程，以及将这些衍生物用作药物的用途。
• Chemical Compounds 572
  申请人：Berger Markus

  公开号：US20100197644A1

  公开（公告）日：2010-08-05

  Compounds of formula (I): The present invention relates to novel indazolyl ester or amide derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments

  式(I)的化合物：本发明涉及新型吲哚酰基或酰胺衍生物，以及包含这些衍生物的制药组合物，制备这些新型衍生物的方法以及将这些衍生物用作药物的用途。
• INDAZOLYL AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS
  申请人：AstraZeneca AB

  公开号：EP2102169B1

  公开（公告）日：2012-06-20
• US7728030B2
  申请人：——

  公开号：US7728030B2

  公开（公告）日：2010-06-01
• US8143290B2
  申请人：——

  公开号：US8143290B2

  公开（公告）日：2012-03-27